The Cardiovascular Health Study is an observational cohort study of risk factors for cardiovascular disease in 5201 participants, ages 65 years. We report the methods and quality-assurance results for blood procurement, processing, shipping, storage, and sample analysis used during the first examination period (May 1989-June 1990. The most frequent difficulty in phlebotomy and processing was the requirement of more than one venipuncture (in 2.6% of the participants). The CVs for control materials ranged from 0.93% for glucose to 10.7% for insulin; most were <4%. In addition to standard quality-assurance methods, we applied two other methods: technical error calculation for replicates, and weighted linear regression to assess time trend in results of control materials. After outliers were excluded, technical error values ranged from 1.7 for uric acid to 18.8 for insulin. Factor VII and factor VIII had slight trends over the 12-month analysis period. Results of quality-assurance analyses used to resolve problems were successful, thereby improving the second laboratory examination.
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In multicenter epidemiological studies involving laboratory analyses, it is important to have a central laboratory that maintains high standards for procurement and analysis of blood samples, efficient and accurate data transfer to a coordinating center, and internal and external quality assurance practices for these components.
This ensures accuracy, precision, and center-to-center comparability of the results obtained, so that meaningful conclusions may be made from data. Several large studies have demonstrated the success of these systems (1) (2) (3) .
The Cardiovascular Health Study (CHS) is a multicenter longitudinal study of risk factors for cardiovascular disease in 5201 adults, ages 65 years (4 ). Four field centers perform baseline examinations, transmit data to the Coordinating Center at the University of Washington (Seattle, WA), and send blood samples to the Central Blood Analysis Laboratory (CBAL) at the University of Vermont (Burlington, VT).
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Here we describe blood sample acquisition, analytic and quality-assurance methods, and provide the results of quality-assurance analysis for the baseline cohort assessment in CHS. This evaluation covered 1 year, beginning in May 1989. The study was approved by each institution's committee for human subjects research.
Materials and Methods
The CBAL consists of the Medical Center Hospital of of the number of aliquots reported sent by the field center and the number received, and (I)the sample volumes for each color-coded aliquot. Quality-assurance results for phlebotomy, processing, and shipping were summarized and transmitted to the Coordinating Center weekly, to identiQy systematic or random problems.
Sample Repository and Quality Assurance
Each CHS participant was assigned a consecutive CBAL identification number, which was recorded with the field center blood identification number on a master list. All samples were stored in four -70#{176}C chest freezers (Revco, Asheville, NC) in a temperature-controlled room (65-70#{176}F).
Short-term storage included samples for chemistry, lipid, and coagulation assays for the baseline CHS examination.
Long-term storage samples were used for later analyses of the cohort. All samples were stored numerically by CBAL number in color-coded boxes arranged in freezers, and coded in a computerized freezer log. Hematocrit, platelet, and white blood cell counts were measured on automated instruments at local hematology laboratories near each field center. Although monthly internal and external quality-assurance reports were examined, these results are not reported here.
Replicate studies.
Replicate samples from a subset of the CHS cohort (3%) were submitted to establish the precision of assays. The replicate samples were obtained from the same blood-collection tube as the test specimen, were stored at the field center for -1 week, then shipped to the CBAL. They were included, in blinded fashion, in routine runs. Analysis of results was made monthly and reported to the Quality Control Committee of the CHS. Analysis included paired twotailed t-tests to determine the significance of any difference between the original sample and the replicate sample values. Pearson correlation coefficients of pairs and technical error were also determined.
The technical error calculation for each analyte over the evaluation period was used to estimate the significance of the summation of the differences between replicate pairs in the context of the overall results for the population (12) Gbyte hard-disk storage. These databases consist of sample repository data and results for all assays. Assay results were collected daily on floppy disks and hard copy sheets. The disks were merged with the database and entries were checked with hard copy sheets. Manually entered results were verified by a second technician. The databases were backed up each evening on high-speed tape (current procedure uses removable hard disks). Previously untransmitted data were transmitted to the Coordinating Center weekly by E-mail (MCI Mail and Lotus Express) and the CBAL database was maintained as a backup. There were call-back values for triglycerides, glucose, potassium, and creatinine. The field center physicians were notified by the CBAL of any values exceeding the call-back value. Complete assay results were regularly sent to the field centers for review. The field center physicians sent results of all blood assays (except factors VII and VIII) with reference ranges to participants.
Results

Phlebotomy/Processing
There were 5179 Phlebotomy/Processing Forms received with accompanying blood samples in a form suitable for further analysis. Table 2 summarizes problems encountered with phlebotomy and processing. The most common problem was requirement of multiple sticks (2.6% of participants).
Common causes of this included inability to enter the vein and loss of blood flow during the draw. There were infrequent problems with processing and shipping. The most frequent problem was incorrect labeling of samples, which most often consisted of an incorrect participant number label within one participant's bag of aliquots (1.3% of participants). This was resolved for each occurrence by telephone with the field center. Table 3 . The most common reason for call-back was hyperglycemia, representing 9 1.6% of all call-backs.
Sample Repository
The CBAL processed 65 057 aliquots for long-term storage. For the citrated collection tubes, the most efficient type for obtaining complete aliquots, >99% of participants' samples yielded the full number of aliquots desired. The most difficult sample type for obtaining complete aliquots was the serum sample (70% yield). Table 4 shows results of internal quality-assurance analysis of the control materials described for the 12 analytes tested. There was variability among analytes in the total number of control assays run. This was due to frequency of control samples per run of participant samples, batch sizes, and total number of runs performed for each analyte. Only three control pools had average monthly CVs >10%:
Quality Assurance for Assays
one of the two control pools for factor VIII (10.37%) and two different lots of the insulin control pool (10.68% and 10.98%). The average monthly CVs for all other assays were <4% except for factor VII (4.7% and 5.9% for two different control materials).
Replicate Studies
Results of replicate studies are summarized in Table  5 . Replicate samples were analyzed in blinded fashion on an average of 3.3% of the 5201 participants per assay. The mean values for participant samples and replicate samples are shown. The differences of these means for each analyte were statistically significant for four analytes: albumin, factor VII, factor VIII, and fibrinogen.
Pearson correlation coefficients between replicate pairs ranged from 0.733 (factor VIII) to 0.990 (creatinine) with a mean of 0.897. b Total no. of control assays (n) is an average of 4.7% greater than the number of assays for which the overall quality control (OC) pool average and overall
CVwere determined.
Insulin control lot B was used for 2 months at the end of the study. Mean and SEM of the participants' samples (1) and the replicate samples (2);units as in Table 4 . All pairs were not significantly different by two-tailed t-tests (P >0.05), except those marked b (P <0.0001) and C <0.05).
d Outliers were excluded if the difference between the participant sample and its replicate was >3 SD from the mean difference of the overall group of pairs for each assay.
#{149} Adjusted values determined after exclusion of outliers. Approximate CV, as derived from the technical error determination, is shown for comparison with analytical CVin Table 4 [for large sample size, technical error = CV (V)].
For the year examined, the monthly mean values for technique. For sample processing the two prominent the control materials were analyzed for trend by weighted problems were labeling errors and low yield of the factor VII and factor VIII, of the 12 assays tested, exhibited a trend. The regression coefficients for factor VII and factor VIII were 0.6 and -1.0%/month, respectively.
Discussion
Phlebotomy,
Processing, and Sample Repository
There was a notable lack of difficulty in phlebotomy serum sample. Labeling errors resulted in exclusion of 22 participants' samples (4.2%) from laboratory analysis. This was identified to the field centers, and the use of blood identification numbers on specimens in addition to separate participant identification numbers was eliminated.
This resolved the labeling problem, resulting in a preliminary estimate of <0.1% labeling errors for aliquot identification in the second-examination blood collection.
The low yield (70%) of the serum sample was thought to be due to allowing too short a time for clot retraction prior to removal of serum from the blood tube. The processing instructions for the serum sample for subsequent draws were changed, increasing the minimum time for clot retraction to 40 mm. The yield of a full set of aliquots improved from 70.2% to 87.3% for the second-examination blood collection.
Assay Quality Assurance
The assay quality-assurance evaluation documents the maintenance of high levels of accuracy and precision in this large cohort study. The evaluation consisted of (a) determination at the low end of the normal range (mean 54% and 65% for two materials), and thus may overestimate any actual measurement error in the CHS sample (mean 122%).
Mean monthly CVs for fibrinogen (all <3.5% for four control materials), factor VII (4.72% and 5.9% for two control materials), and factor VIII compare favorably with the range of monthly CVs reported by the ARIC investigators (fibrinogen, 3-5%; factor VII, 3-8%; factor VIII, 4-10%) (2). This confirms that hemostatic factors can be measured reliably in large multicenter studies if appropriate methods for sample acquisition and analysis are used.
The ranges of the monthly CVs for all control materials were generally narrow, indicating consistency of results. The overall yearly CVs for all analytes were only slightly higher than the average monthly CVs, indicative of a small component of the cumulative error that is expected to occur longitudinally in any laboratory. The overall yearly CV for the cholesterol measurement was less than that recommended by the National Cholesterol Education Panel (13) .
The replicate pairs evaluated blindly for four assays (albumin, factor VII, factor VIII, and fibrinogen) were significantly different from each other as assessed by paired two-tailed t-tests. There may have been a systematic effect related to the 1-2-week time difference in testing of the replicate samples. However, in our experience with storage at -70#{176}C, this seems unlikely for these analytes. Also, P 0.05 indicated statistical significance. In many studies with similarly large numbers of analyses, a correction to the P value is used. At P 0.01, only factor VII and albumin were significantly different.
In addition, this analysis included outlier values, and therefore may overestimate the difference between pairs attributable to analytical variation. Finally, the mean differences between pairs for these four analytes were relatively small and of little analytical significance. We will use year 5 examination results to determine if this recurs.
After outlier exclusion, blind replicate analysis revealed a mean adjusted Pearson correlation coefficient between replicate pairs of 0.944, compared with an unadjusted mean of 0.897. We believe the outlier exclusion was valid because the majority of outliers were due to labeling error, so that these pairs were not true replicates. However, the exclusion of outliers in any analysis may introduce the potential for overcorrection of the data.
Correlation coefficients provide an assessment of association between blind replicate measures, but do not consider the level of agreement in the context of the population distribution.
Therefore, technical error was also used to estimate precision in the replicate analysis. After exclusion of outliers, adjusted technical errors did not correspond perfectly to correlation coefficients (Table 5 ). For example, albumin exhibited a relatively low correlation coefficient compared with creatinine.
However, the technical error values were comparable, indicating similar magnitudes of error in the context of the respective population distributions. We suggest that technical error assessment should be used more commonly in the analysis of laboratory data from large studies such as CHS.
Trend analysis indicated general consistency of control material results. The most important finding, a significant negative trend for factor VIII, was found to be due to a decrease in the value for the factor VIII control pool in month 8 of the study. The reason for this change was not clearly elucidated; no change of control material, calibration reference, or technique was identified.
In conclusion, the design and careful management of a system for blood analysis is critical to the success of a longitudinal cohort study. We have demonstrated that high-quality blood acquisition and analysis can be accomplished for a large, multicenter study such as CHS. An organized system of quality assurance was successful in identi1ying problems in phlebotomy, blood processing, shipping, and repository management so that solutions could be applied. In addition, much was learned to facilitate improved methods for the second laboratory examination of the CHS cohort in year 5 of the study.
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